Actively Recruiting
Insulin Regulation of Lipolysis and Lipolysis Proteins
Led by Mayo Clinic · Updated on 2026-01-28
64
Participants Needed
1
Research Sites
424 weeks
Total Duration
On this page
Sponsors
M
Mayo Clinic
Lead Sponsor
N
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborating Sponsor
AI-Summary
What this Trial Is About
These studies will define the abnormalities in the adipocyte proteins that are involved in the failure of insulin to suppress lipolysis normally in humans with upper body obesity and will help discover the mechanism by which pioglitazone, a medication used to treat type 2 diabetes and improve insulin resistance, improves insulin-regulation of adipocyte fatty acid metabolism.
CONDITIONS
Official Title
Insulin Regulation of Lipolysis and Lipolysis Proteins
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Men and Women between the ages of 18 and 55.
- Women will be premenopausal
- Non obese adults BMI between 18-25
- Obese BMI 30-38
You will not qualify if you...
- Patients with established New York Heart Associations (NYHA) class III or IV Heart failure.
- Known hypersensitivity to pioglitazone or any other component of ACTOSE.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Mayo Clinic in Rochester
Rochester, Minnesota, United States, 55905
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
BASIC_SCIENCE
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here